Clinical trial · Observational
Myeloma Novel Drug Discovery Ver 1.2
Investigation of the Activity of Novel Compounds for the Treatment of Myeloma and Mechanisms of Drug Resistance to Current Therapies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observational study - sample collection only. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Participants with a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder
- description
- Participants who are undergoing peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment will be approached to collect additional samples for research.
- interventionNames
- Other: Observational study - sample collection only.
Primary outcomes (1)
- measure
- Cell viability
- timeFrame
- 12 months
- description
- Myeloma cell viability when incubated with standard of care and novel compounds.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Participants who have a diagnosis, or suspected diagnosis, of myeloma or related plasma cell disorder 2. Participants who are undergoing a peripheral blood or bone marrow aspirate sampling for diagnostic, staging or follow-up purposes, before, whilst or after receiving anti-myeloma treatment 3. Participants aged 18 years of age or above 4. Participants willing to consent to an additional sample being taken at the time of their peripheral blood or bone marrow aspirate sampling Exclusion Criteria: 1. Participants unable to provide consent 2. Participants with known active infectious diseases (e.g. HIV, Hepatitis B/C, COVID) that pose a risk to the use of the sample in the laboratory
References
Publications (0)
Data not yet available